SEC Filing | PetIQ, LLC

View:

petq-20230930

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
¨			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-38163

PetIQ, Inc.

(Exact name of registrant as specified in its charter)


Delaware			35-2554312
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
230 E. Riverside Dr.			83616
Eagle, Idaho			(Zip Code)
(Address of principal executive offices)

208-939-8900

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading
Symbol

Name of Each Exchange on Which Registered

Class A Common Stock, $0.001 par value

PETQ

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	¨	Accelerated filer	x
Non-accelerated filer	¨	Smaller reporting company	¨
Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes x No

As of November 7, 2023, we had 29,187,756 shares of Class A common stock and 239,540 shares of Class B common stock outstanding.

PetIQ, Inc.

Table of Contents


			Page

Part I.	Financial Information		3

	Item 1.	Condensed Consolidated Financial Statements (Unaudited)	3
		PetIQ, Inc. Condensed Consolidated Balance Sheets	4
		PetIQ, Inc. Condensed Consolidated Statements of Operations	5
		PetIQ, Inc. Condensed Consolidated Statements of Comprehensive Income (Loss)	6
		PetIQ, Inc. Condensed Consolidated Statements of Cash Flows	7
		PetIQ, Inc. Condensed Consolidated Statements of Equity	9
		PetIQ, Inc. Notes to Condensed Consolidated Financial Statements	11
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32
	Item 4.	Controls and Procedures	33

Part II.	Other Information

	Item 1.	Legal Proceedings	33
	Item 1A.	Risk Factors	33
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34
	Item 3.	Defaults Upon Senior Securities	34
	Item 4.	Mine Safety Disclosures	34
	Item 5.	Other Information	34
	Item 6.	Exhibits	35

Signatures			36

PART I —FINANCIAL INFORMATION

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continuing,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “project,” “should,” “will,” and similar expressions. Examples of forward-looking statements include, without limitation:

•statements regarding our strategies, results of operations or liquidity;

•statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance;

•statements of management’s goals and objectives; and

•assumptions underlying statements regarding us or our business.

Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances, or achievements expressed or implied by the forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, factors discussed under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q; general economic or market conditions, including the impacts of the global economic slowdown, increased inflation, rising interest rates, global conflict and recent and potential bank failures; our ability to improve profitability and achieve the anticipated cost savings and reinvestment from the Services segment, the anticipated costs associated with the optimization and the success of our remaining wellness centers following the optimization; our ability to successfully grow our business through acquisitions and our ability to integrate acquisitions, including Rocco & Roxie; our dependency on a limited number of customers; labor shortages, strikes, lock outs, walk offs or other disruptions to labor; our ability to implement our growth strategy effectively; our ability to manage our manufacturing and supply chain effectively; disruptions in our manufacturing and distribution chains; competition from veterinarians and others in our industry; reputational damage to our brands; economic trends and spending on pets; the effectiveness of our marketing and trade promotion programs; recalls or withdrawals of our products or product liability claims; our ability to introduce new products and improve existing products; our failure to protect our intellectual property; costs associated with governmental regulation; war, conflict, insurrection, pandemic, revolution, riot or severe weather; our ability to keep and retain key employees; our ability to sustain profitability; and the risks set forth under the “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022 and this Quarterly Report on Form 10-Q for the period ended September 30, 2023, and other reports filed from time to time with the Securities and Exchange Commission.

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results. The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Consequently, you should not place undue reliance on forward-looking statements.


PetIQ, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in 000’s except for per share amounts)


	September 30, 2023		December 31, 2022
Current assets
Cash and cash equivalents	$	124,614	$	101,265
Accounts receivable, net	151,680		118,004
Inventories	128,126		142,605
Other current assets	6,241		8,238
Total current assets	410,661		370,112
Property, plant and equipment, net	62,927		73,395
Operating lease right of use assets	12,289		18,231
Other non-current assets	2,373		1,373
Intangible assets, net	164,644		172,479
Goodwill	204,195		183,306
Total assets	$	857,089	$	818,896
Liabilities and equity
Current liabilities
Accounts payable	$	113,449	$	112,995
Accrued wages payable	19,162		11,512
Accrued interest payable	7,915		1,912
Other accrued expenses	9,133		7,725
Current portion of operating leases	6,877		6,595
Current portion of long-term debt and finance leases	8,105		8,751
Total current liabilities	164,641		149,490
Operating leases, less current installments	8,783		12,405
Long-term debt, less current installments	439,210		443,276
Finance leases, less current installments	617		907
Other non-current liabilities	4,667		1,025
Total non-current liabilities	453,277		457,613
Equity
Additional paid-in capital	385,839		378,709
Class A common stock, par value $0.001 per share, 125,000 shares authorized; 29,558 and 29,348 shares issued, respectively	29		29
Class B common stock, par value $0.001 per share, 8,402 shares authorized; 239 and 252 shares issued and outstanding, respectively	—		—
Class A treasury stock, at cost, 373 shares	(3,857)		(3,857)
Accumulated deficit	(143,115)		(162,733)
Accumulated other comprehensive loss	(1,715)		(2,224)
Total stockholders' equity	237,181		209,924
Non-controlling interest	1,990		1,869
Total equity	239,171		211,793
Total liabilities and equity	$	857,089	$	818,896

See accompanying notes to the condensed consolidated financial statements.


PetIQ, Inc. Condensed Consolidated Statements of Operations (Unaudited, in 000’s except for per share amounts)


	For the Three Months Ended				For the Nine Months Ended
	September 30, 2023		September 30, 2022		September 30, 2023		September 30, 2022

Product sales	$	239,665	$	176,217	$	776,825	$	642,981
Services revenue	37,354		33,508		105,212		94,453
Total net sales	277,019		209,725		882,037		737,434
Cost of products sold	174,286		131,414		585,616		485,833
Cost of services	30,122		27,541		87,671		81,222
Total cost of sales	204,408		158,955		673,287		567,055
Gross profit	72,611		50,770		208,750		170,379
Operating expenses
Selling, general and administrative expenses	55,021		45,984		153,507		144,815
Restructuring	8,235		—		8,235		—
Goodwill impairment	—		47,264		—		47,264
Operating income (loss)	9,355		(42,478)		47,008		(21,700)
Interest expense, net	8,581		7,276		26,137		19,696

Other expense (income), net	35		172		158		(31)
Total other expense, net	8,616		7,448		26,295		19,665
Pretax net income (loss)	739		(49,926)		20,713		(41,365)
Income tax (expense) benefit	(283)		355		(923)		(368)
Net income (loss)	456		(49,571)		19,790		(41,733)
Net income (loss) attributable to non-controlling interest	5		(435)		172		(360)
Net income (loss) attributable to PetIQ, Inc.	$	451	$	(49,136)	$	19,618	$	(41,373)
Net income (loss) per share attributable to PetIQ, Inc. Class A common stock
Basic	$	0.02	$	(1.68)	$	0.67	$	(1.42)
Diluted	$	0.02	$	(1.68)	$	0.67	$	(1.42)
Weighted Average shares of Class A common stock outstanding
Basic	29,181		29,224		29,116		29,224
Diluted	29,715		29,224		29,386		29,224

See accompanying notes to the condensed consolidated financial statements.


PetIQ, Inc. Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited, in 000’s)


	For the Three Months Ended				For the Nine Months Ended
	September 30, 2023		September 30, 2022		September 30, 2023		September 30, 2022
Net income (loss)	$	456	$	(49,571)	$	19,790	$	(41,733)
Foreign currency translation adjustment	277		(942)		513		(2,475)
Comprehensive income (loss)	733		(50,513)		20,303		(44,208)
Comprehensive income (loss) attributable to non-controlling interest	7		(442)		176		(381)
Comprehensive income (loss) attributable to PetIQ, Inc.	$	726	$	(50,071)	$	20,127	$	(43,827)

See accompanying notes to the condensed consolidated financial statements.


PetIQ, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited, in 000’s)


	For the Nine Months Ended September 30,
	2023		2022
Cash flows from operating activities
Net income (loss)	$	19,790	$	(41,733)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Depreciation and amortization of intangible assets and loan fees	35,816		26,564

Loss on disposition of property, plant, and equipment	7		56
Stock based compensation expense	8,059		8,904



Goodwill impairment	—		47,264
Other non-cash activity	672		(7)
Changes in assets and liabilities, net of business acquisition
Accounts receivable	(32,562)		(11,219)
Inventories	16,451		(50,847)
Other assets	2,078		1,924
Accounts payable	(593)		18,957
Accrued wages payable	7,649		1,083
Other accrued expenses	7,362		(1,818)
Net cash provided by (used in) operating activities	64,729		(872)
Cash flows from investing activities

Business acquisition (net of cash acquired)	(27,634)		—
Purchase of property, plant, and equipment	(6,205)		(9,797)

Net cash used in investing activities	(33,839)		(9,797)
Cash flows from financing activities


Proceeds from issuance of long-term debt	35,000		44,000
Principal payments on long-term debt	(40,700)		(49,700)
Repurchase of Class A common stock	—		(3,857)


Principal payments on finance lease obligations	(1,138)		(1,097)

Tax withholding payments on Restricted Stock Units	(984)		(862)
Exercise of options to purchase Class A common stock	—		115
Net cash used in financing activities	(7,822)		(11,401)
Net change in cash and cash equivalents	23,068		(22,070)
Effect of exchange rate changes on cash and cash equivalents	281		(618)
Cash and cash equivalents, beginning of period	101,265		79,406
Cash and cash equivalents, end of period	$	124,614	$	56,718

See accompanying notes to the condensed consolidated financial statements.


PetIQ, Inc. Condensed Consolidated Statements of Cash Flows, Continued (Unaudited, in 000’s)


	For the Nine Months Ended September 30,
Supplemental cash flow information	2023		2022
Interest paid	$	18,139	$	18,550
Property, plant, and equipment acquired through accounts payable	185		376
Finance lease additions	—		59

Income taxes paid, net of refunds	376		258

See accompanying notes to the condensed consolidated financial statements.


PetIQ, Inc. Condensed Consolidated Statements of Equity (Unaudited, in 000’s)


	Three months ended September 30, 2023
	Accumulated Deficit		Accumulated Other Comprehensive Loss		Class A Common			Class A Treasury Stock			Class B Common			Additional Paid-in Capital		Non-controlling Interest		Total Equity
					Shares	Dollars		Shares	Dollars		Shares	Dollars
Balance - July 1, 2023	$	(143,566)	$	(1,990)	29,551	$	29	373	$	(3,857)	244	$	—	$	383,020	$	1,967	$	235,603
Exchange of LLC Interests held by LLC Owners	—		—		5	—		—	—		(5)	—		7		(7)		—

Other comprehensive income	—		275		—	—		—	—		—	—		—		2		277

Stock based compensation expense	—		—		—	—		—	—		—	—		2,827		23		2,850

Issuance of stock vesting of RSU's, net of tax withholdings	—		—		2	—		—	—		—	—		(15)		—		(15)
Net income	451		—		—	—		—	—		—	—		—		5		456
Balance - September 30, 2023	$	(143,115)	$	(1,715)	29,558	$	29	373	$	(3,857)	239	$	—	$	385,839	$	1,990	$	239,171


	Nine months ended September 30, 2023
	Accumulated Deficit		Accumulated Other Comprehensive Loss		Class A Common			Class A Treasury Stock			Class B Common			Additional Paid-in Capital		Non-controlling Interest		Total Equity
					Shares	Dollars		Shares	Dollars		Shares	Dollars
Balance - January 1, 2023	$	(162,733)	$	(2,224)	29,348	$	29	373	$	(3,857)	252	$	—	$	378,709	$	1,869	$	211,793
Exchange of LLC Interests held by LLC Owners	—		—		13	—		—	—		(13)	—		122		(122)		—

Other comprehensive income	—		509		—	—		—	—		—	—		—		4		513

Stock based compensation expense	—		—		—	—		—	—		—	—		7,992		67		8,059

Issuance of stock vesting of RSU's, net of tax withholdings	—		—		197	—		—	—		—	—		(984)		—		(984)
Net income	19,618		—		—	—		—	—		—	—		—		172		19,790
Balance - September 30, 2023	$	(143,115)	$	(1,715)	29,558	$	29	373	$	(3,857)	239	$	—	$	385,839	$	1,990	$	239,171


	Three months ended September 30, 2022
	Accumulated Deficit		Accumulated Other Comprehensive Loss		Class A Common			Class A Treasury Stock			Class B Common			Additional Paid-in Capital		Non-controlling Interest		Total Equity
					Shares	Dollars		Shares	Dollars		Shares	Dollars
Balance - July 1, 2022	$	(106,762)	$	(2,203)	29,304	$	29	—	$	—	252	$	—	$	374,057	$	2,320	$	267,441


Other comprehensive loss	—		(935)		—	—		—	—		—	—		—		(7)		(942)
Treasury stock purchased	—		—		—	—		373	(3,857)		—	—		—		—		(3,857)
Stock based compensation expense	—		—		—	—		—	—		—	—		2,217		21		2,238

Issuance of stock vesting of RSU's, net of tax withholdings	—		—		15	—		—	—		—	—		3		—		3
Net loss	(49,136)		—		—	—		—	—		—	—		—		(435)		(49,571)
Balance - September 30, 2022	$	(155,898)	$	(3,138)	29,319	$	29	373	$	(3,857)	252	$	—	$	376,277	$	1,899	$	215,312


	Nine months ended September 30, 2022
	Accumulated Deficit		Accumulated Other Comprehensive Loss		Class A Common			Class A Treasury Stock			Class B Common			Additional Paid-in Capital		Non-controlling Interest		Total Equity
					Shares	Dollars		Shares	Dollars		Shares	Dollars
Balance - January 1, 2022	$	(114,525)	$	(684)	29,139	$	29	—	$	—	272	$	—	$	368,006	$	2,394	$	255,220
Exchange of LLC Interests held by LLC Owners	—		—		20	—		—	—		(20)	—		192		(192)		—

Other comprehensive income	—		(2,454)		—	—		—	—		—	—		—		(21)		(2,475)
Treasury stock purchased	—		—		—	—		373	(3,857)		—	—		—		—		(3,857)
Stock based compensation expense	—		—		—	—		—	—		—	—		8,826		78		8,904
Exercise of Options to purchase common stock	—		—		2	—		—	—		—	—		115		—		115
Issuance of stock vesting of RSU's, net of tax withholdings	—		—		158	—		—	—		—	—		(862)		—		(862)
Net loss	(41,373)		—		—	—		—	—		—	—		—		(360)		(41,733)
Balance - September 30, 2022	$	(155,898)	$	(3,138)	29,319	$	29	373	$	(3,857)	252	$	—	$	376,277	$	1,899	$	215,312

Note that certain figures shown in the tables above may not recalculate due to rounding.

See accompanying notes to the condensed consolidated financial statements.

PetIQ Inc.

Notes to the Condensed Consolidated Financial Statements (unaudited)

Note 1 — Principal Business Activity and Significant Accounting Policies

Principal Business Activity and Principles of Consolidation

PetIQ, Inc. ("PetIQ", the "Company", "we", "our", or "us") is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. We engage with customers through more than 60,000 points of distribution across retail and e-commerce channels with our branded and distributed medications as well as health and wellness items, which are further supported by our world-class medications manufacturing facility in Omaha, Nebraska and health and wellness manufacturing facility in Springville, Utah. Our national service platform operates in over 2,600 retail partner locations in 41 states, providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care that we can give them.

PetIQ has two reporting segments: (i) Products; and (ii) Services. The Products segment consists of our manufacturing and distribution business. The Services segment consists of veterinary and wellness services and related product sales provided by the Company directly to consumers.

PetIQ is the managing member of PetIQ Holdings, LLC (“HoldCo”), a Delaware limited liability company, which is the sole member of PetIQ, LLC (“OpCo”) and, through HoldCo, operates and controls all of the business and affairs of OpCo.

The condensed consolidated financial statements as of September 30, 2023 and December 31, 2022 and for the three and nine months ended September 30, 2023 and 2022 are unaudited. The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited financial statements at that date but does not include all of the disclosures required by U.S. GAAP. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2022 and related notes thereto included in the most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2023 (the "Annual Report"). Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant, and equipment and intangible assets; the valuation of property, plant, and equipment, intangible assets and goodwill, the valuation of deferred tax assets, the valuation of inventories, and reserves for legal contingencies.

Significant Accounting Policies

The Company's significant accounting policies are discussed in Note 1 – Principal Business Activity and Significant Accounting Policies in the Annual Report. There have been no significant changes to these policies that have had a material impact on the Company's unaudited condensed financial statements and related notes during the three and nine months ended September 30, 2023.

Note 2 — Business Combination

Rocco & Roxie

The Company completed the acquisition of all of the membership units of Rocco & Roxie Supply Co, LLC ("R&R") on January 13, 2023 (the "R&R Acquisition"), which resulted in R&R becoming a wholly owned subsidiary of the Company. The R&R Acquisition expands the Company's brand and product portfolio to include stain and odor products and enables the Company to extend its offerings into premium dog supplements and jerky treats. The Company paid $26.5 million for the membership interests of R&R using cash on hand. The purchase was subject to normal working capital adjustments.

The following table summarizes the final allocations of the consideration paid of $27.6 million, which included the $26.5 million purchase price plus $1.1 million of working capital, to the assets acquired and liabilities assumed, based on the fair value at the date of the R&R Acquisition:


$'s in 000's	Fair Value
Current assets	$	3,020
Other assets	1,208
Amortizable intangibles
Trade name	7,100
Customer relationships	320
Total amortizable intangibles	$	7,420
Goodwill	20,641
Total assets	$	32,289

Current liabilities	1,000
Other tax liabilities	3,655
Total liabilities	4,655

Purchase price, net of cash acquired	$	27,634

Intangible assets will be amortized over the estimated useful lives of the assets through January 2033. The weighted average amortization period of the amortizable intangible assets is approximately 9.9 years. The identifiable intangible assets are measured at fair value as Level III in accordance with the fair value hierarchy.

Goodwill represents the future economic benefits that do not qualify for separate recognition and primarily includes the assembled workforce and other non-contractual relationships, as well as expected future synergies. Approximately $19.4 million of the $20.6 million of Goodwill will not be tax deductible, and the remaining balance is expected to be deductible for tax purposes. Goodwill was allocated to the Products segment. Transaction costs of $0.5 million were incurred and are recorded in Selling, General, and Administrative costs on the condensed consolidated statement of operations.

Note 3 — Debt

Senior Secured Asset-Based Revolving Credit Facility

On April 13, 2021, OpCo entered into an asset-based revolving credit agreement with KeyBank National Association, as administrative agent and collateral agent, and the lenders’ party thereto, that provides revolving credit commitments of $125.0 million, subject to a borrowing base limitation (the "ABL"). The borrowing base for the ABL at any time equals the sum of: (i) 90% of eligible investment-grade accounts receivable; plus (ii) 85% of eligible other accounts receivable; plus, (iii) 85% of the net orderly liquidation value of the cost of certain eligible on-hand and in-transit inventory; plus, (iv) at the option of OpCo, 100% of qualified cash; minus (v) reserves. The ABL bears interest at a variable rate plus a margin, with the variable rate being based on a base rate or LIBOR at the option of the Company. On February 3, 2023, HoldCo and Opco, entered into the First Amendment Agreement to the ABL to replace the interest rate benchmark from LIBOR to Secured Overnight Financing Rate ("SOFR"). The interest rate at September 30, 2023 was 6.84%. The Company also pays a commitment fee on unused borrowings at a rate of 0.35%.

The ABL Facility is secured by substantially all the assets of HoldCo and its wholly-owned domestic subsidiaries including a first-priority security interest in personal property consisting of accounts receivable, inventory, cash, and deposit accounts (such collateral subject to first-priority security interest, "ABL Priority Collateral"), and a second-priority security interest in all other personal and real property of HoldCo and its wholly-owned domestic subsidiaries (such collateral subject to such second-priority security interest, “Term Priority Collateral”), in each case, subject to customary exceptions. The ABL contains customary representations and warranties, affirmative and negative covenants and events of default, including negative covenants that restrict the ability of HoldCo and its restricted subsidiaries to incur additional indebtedness, pay

dividends, make investments, loans, and acquisitions, among other restrictions. As of September 30, 2023, no amounts were outstanding under the ABL.

Senior Secured Term Loan Facility - Term Loan B

On April 13, 2021, OpCo entered into a term credit and guaranty agreement with Jefferies Finance LLC, as administrative agent and collateral agent, and the lenders’ party thereto, that provides senior secured term loans of $300.0 million (which may be increased in certain circumstances) (the "Term Loan B"). The Term Loan B bears interest at a variable rate of either prime, federal funds effective rate or LIBOR, plus an applicable margin of between 3.25% and 4.25% depending on the underlying base rate. LIBOR rates are subject to a 0.50% floor. . The Term Loan B requires quarterly payments of 0.25% of the original principal amount, with the balance due on April 13, 2028. On May 25, 2023, the Term Loan B was amended to replace the interest rate benchmark from the Adjusted Eurodollar Rate to SOFR. The interest rate at September 30, 2023 was 9.84%

The Term Loan B is secured by substantially all the assets of HoldCo and its wholly-owned domestic subsidiaries, including a first-priority security interest in Term Priority Collateral and a second-priority security interest in ABL Priority Collateral, in each case, subject to customary exceptions. The Term Loan B contains customary representations and warranties, affirmative and negative covenants and events of default, including negative covenants that restrict the ability of HoldCo and its restricted subsidiaries to incur additional indebtedness, pay dividends, make investments, loans, and acquisitions, among other restrictions.

Convertible Notes

On May 19, 2020, the Company issued $143.8 million in aggregate principal amount of 4.00% Convertible Senior Notes due 2026 (the “Notes”) pursuant to the indenture (the “Indenture”), dated as of May 19, 2020. The Notes accrue interest at a rate of 4.00% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020. The Notes will mature on June 1, 2026, unless earlier repurchased, redeemed or converted. Before January 15, 2026, holders will have the right to convert their Notes only upon the occurrence of certain events. From and after January 15, 2026, holders may convert their Notes at any time at their election until the close of business on the scheduled trading day immediately before the maturity date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of its Class A common stock, or a combination of cash and shares of its Class A common stock, at its election. The initial conversion rate is 33.7268 shares of Class A common stock per $1,000 principal amount of Notes. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.

The following represents the Company’s long-term debt as of:


$'s in 000's	September 30, 2023		December 31, 2022
Convertible Notes	$	143,750	$	143,750
Term Loan B	293,250		295,500
Revolving credit facility	—		—
Other debt	16,642		19,690
Net discount on debt and deferred financing fees	(7,096)		(8,531)
	$	446,546	$	450,409
Less current maturities of long-term debt	(7,336)		(7,133)
Total long-term debt	$	439,210	$	443,276

Future maturities of long-term debt, excluding the discount on debt and deferred financing fees, as of September 30, 2023, are as follows:


($'s in 000's)
Remainder of 2023	$	1,766
2024	7,426
2025	4,600
2026	147,350
2027	3,600
Thereafter	288,900

Note 4 — Intangible Assets and Goodwill

Goodwill and non-amortizable intangible assets

Intangible assets consist of the following at:


$'s in 000's	Useful Lives	September 30, 2023		December 31, 2022
Amortizable intangibles
Certification	7 years	$	350	$	350
Customer relationships	10-20 years	160,418		160,040
Patents and processes	5-10 years	14,731		14,634
Brand names	5-15 years	31,778		24,633
Total amortizable intangibles		207,277		199,657
Less accumulated amortization		(75,872)		(62,085)
Total net amortizable intangibles		131,405		137,572
Non-amortizable intangibles
Trademarks and other		33,239		33,239
In-process research and development		—		1,668
Intangible assets, net of accumulated amortization		$	164,644	$	172,479

Certain intangible assets are denominated in currencies other than the U.S. Dollar; therefore, their gross and net carrying values are subject to foreign currency movements. Amortization expense for the three months ended September 30, 2023 and 2022 was $4.5 million and $4.6 million, respectively. Amortization expense for the nine months ended September 30, 2023, and 2022 was $15.3 million and $13.6 million, respectively. During the nine months ended September 30, 2023, the Company opted out of the final acquired project included in in-process research and development, effectively abandoning the associated research and development effort. Accordingly, the Company wrote off the associated intangible asset of $1.7 million in the Products segment, the expense for which is included as amortization expense in selling, general and administrative expenses on the condensed consolidated statement of operations for the nine months ended September 30, 2023.

Estimated future amortization expense for each of the following years is as follows:


Years ending December 31, ($'s in 000's)
Remainder of 2023	$	4,510
2024	15,839
2025	15,110
2026	14,415
2027	13,702
Thereafter	67,829

The following is a summary of the changes in the carrying value of goodwill for the period from January 1, 2022 to September 30, 2023:


	Reporting Unit
($'s in 000's)	Products		Services		Total
Goodwill as of January 1, 2022	$	183,846	$	47,264	$	231,110
Foreign currency translation	(540)		—		(540)
Impairment	—		(47,264)		(47,264)
Goodwill as of December 31, 2022	183,306		—		183,306
R&R Acquisition	20,641		—		20,641
Foreign currency translation	248		—		248
Goodwill as of September 30, 2023	$	204,195	$	—	$	204,195

Note 5 — Income Tax

The Company’s tax provision for interim periods is determined by using an estimated annual effective tax rate, adjusted for discrete items arising in that quarter. In each quarter, the Company updates the estimated annual effective tax rate and makes a year-to-date adjustment to the provision. The estimated annual effective tax rate is subject to significant volatility due to several factors, including our ability to accurately predict the Company’s pre-tax and taxable income and loss and the mix of jurisdictions to which they relate.

Our effective tax rate from continuing operations was 38.3% and 4.5% for the three and nine months ended September 30, 2023, respectively, and 0.7% and (0.9%) for the three and nine months ended September 30, 2022, respectively, including discrete items. Income tax expense for the three and nine months ended September 30, 2023 and 2022 was different than the U.S federal statutory income tax rate of 21% primarily due to the effects of the change in valuation allowance, state taxes, and the foreign rate differential.

The Company has assessed the realizability of the net deferred tax assets as of September 30, 2023 and in that analysis has considered the relevant positive and negative evidence available to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income to realize its deferred tax assets. The Company believes it is more likely than not that the benefit from recorded deferred tax assets will not be realized. In future periods, if we conclude we have future taxable income sufficient to recognize the deferred tax assets, we may reduce or eliminate the valuation allowance.

Note 6 — Earnings per Share

Basic and Diluted Earnings (Loss) per Share

Basic earnings (loss) per share of Class A common stock is computed by dividing net income (loss) available to PetIQ, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted earnings (loss) per share of Class A common stock is computed by dividing net income (loss) available to PetIQ, Inc. by the weighted-average number of shares of Class A common stock outstanding adjusted to give effect to potentially dilutive securities.

The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings (loss) per share of Class A common stock:


	Three months ended September 30,				Nine months ended September 30,
(in 000's, except for per share amounts)	2023		2022		2023		2022
Numerator:
Net income (loss)	$	456	$	(49,571)	$	19,790	$	(41,733)
Less: net income (loss) attributable to non-controlling interests	5		(435)		172		(360)
Net income (loss) attributable to PetIQ, Inc. — basic and diluted	451		(49,136)		19,618		(41,373)


Denominator(1):
Weighted-average shares of Class A common stock outstanding — basic	29,181		29,224		29,116		29,224
Dilutive impact of share-based compensation awards (2)	534		—		270		—
Dilutive effect of conversion of Notes (3)	—		—		—		—
Weighted-average shares of Class A common stock outstanding — diluted	29,715		29,224		29,386		29,224

Income (loss) per share of Class A common stock — basic	$	0.02	$	(1.68)	$	0.67	$	(1.42)
Income (loss) per share of Class A common stock — diluted	$	0.02	$	(1.68)	$	0.67	$	(1.42)

(1) Shares of the Company’s Class B common stock do not share in the earnings of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share of Class B common stock under the two-class method has not been presented.

(2) For the three and nine months ended September 30, 2023, 1,367 thousand and 2,142 thousand of outstanding share-based compensation awards were excluded from the computation of diluted earnings per share, as the effect of including those shares would be anti-dilutive. For the three and nine months ended September 30, 2022, 2,571 thousand and 2,194 thousand of outstanding share-based compensation awards were excluded from the computation of diluted earnings per share, as the effect of including those shares would be anti-dilutive.

(3) For the three and nine months ended September 30, 2023 and 2022, 4,848 thousand shares of common stock associated with the assumed conversion of the Notes have been excluded from the computation of diluted earnings per share, as the effect of including those shares would be anti-dilutive.

Note 7 — Stock Based Compensation

PetIQ, Inc. Omnibus Incentive Plan

The Amended and Restated PetIQ, Inc. Omnibus Incentive Plan, (the “Plan”), provides for the grant of various equity-based incentive awards to directors of the Company, employees, and consultants. The types of equity-based awards that may be granted under the Plan include: stock options, stock appreciation rights, restricted stock, restricted stock units ("RSUs"), and other stock-based awards, up to a total of 5,804,000 shares of Class A common stock issuable under the Plan. As of September 30, 2023 and 2022, 1,105,658 and 2,081,000 shares were available for issuance under the Plan, respectively. All awards issued under the Plan may only be settled in shares of Class A common stock. Shares issued pursuant to awards under the incentive plans are from our authorized but unissued shares.

PetIQ, Inc. 2018 Inducement and Retention Stock Plan for CVC Employees

The PetIQ, Inc. 2018 Inducement and Retention Stock Plan for CVC Employees (the “Inducement Plan”) provided for the grant of stock options to employees hired in connection with an acquisition in 2018 as employment inducement awards pursuant to NASDAQ Listing Rule 5635(c)(4). The Inducement Plan reserved 800,000 shares of Class A common stock of the Company, of which 760,000 were granted. No further grants may be made under the Inducement Plan. All awards issued under the Inducement Plan may only be settled in shares of Class A common stock.

Stock Options

The Company awards stock options to certain employees under the Plan and previously issued stock options under the Inducement Plan, which are subject to time-based vesting conditions, typically 25% on each anniversary of the grant date until fully vested. Upon a termination of service relationship by the Company, all unvested options are typically forfeited and the shares of common stock underlying such awards will become available for issuance under the Plan. The maximum contractual term for stock options is 10 years.

The fair value of these equity awards is amortized to equity based compensation expense over the vesting period, which totaled $0.4 million and $1.3 million for the three and nine months ended September 30, 2023, respectively, and $0.5 million and $2.7 million for the three and nine months ended September 30, 2022, respectively. All stock based compensation expense is included in selling, general and administrative expenses based on the role of recipients. The fair value of the stock option awards was determined on the grant dates using the Black-Scholes valuation model based on the following weighted-average assumptions for the nine months ended September 30, 2022. No options were issued for the nine months ended September 30, 2023:


	September 30, 2022
Expected term (years) (1)	6.25
Expected volatility (2)	37.21	%
Risk-free interest rate (3)	1.44	%
Dividend yield (4)	0.00	%

(1)The Company utilized the simplified method to determine the expected term of the stock options since we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.

(2)The expected volatility assumption was calculated based on a peer group analysis of stock price volatility with a look back period consistent with the expected option term.

(3)The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant, which corresponds to the expected term of the stock options.

(4)The Company has not paid and does not anticipate paying a cash dividend on our common stock.

As of September 30, 2023, total unrecognized compensation cost related to unvested stock options was $2.1 million and is expected to be recognized over a weighted-average period of 1.2 years.


	Stock Options (in 000's)	Weighted Average Exercise Price		Aggregate Intrinsic Value (in 000's)		Weighted Average Remaining Contractual Life (years)
Outstanding at January 1, 2022	1,768	$	26.51	$	2,897	7.3
Granted	83	14.16
Exercised	(2)	19.49		$	10
Forfeited	(110)	29.24
Cancelled	(86)	31.12
Outstanding at December 31, 2022	1,652	$	25.48	$	53	6.2


Forfeited	(90)	18.31
Cancelled	(46)	31.54
Outstanding at September 30, 2023	1,516	$	25.69	$	964	4.9
Options exercisable at September 30, 2023	1,306

Restricted Stock Units

The Company awards RSUs to certain employees and directors under the Plan, which are subject to time-based vesting conditions. Typically, upon a termination of service relationship by the Company, all unvested RSUs will be forfeited and the shares of common stock underlying such awards will become available for issuance under the Plan. The fair value of RSUs are measured based on the closing fair market value of the Company’s Class A common stock on the date of grant. At September 30, 2023, total unrecognized compensation cost related to unvested RSUs was $26.1 million and is expected to vest over a weighted average period of 3.1 years.

The fair value of these equity awards is amortized to equity based compensation expense over the vesting period, which totaled $2.5 million and $6.8 million for the three and nine months ended September 30, 2023, and $1.7 million and $6.1 million for the three and nine months ended September 30, 2022, respectively. All stock based compensation expense is included in selling, general and administrative expenses based on the role of recipients.

The following table summarizes the activity of the Company’s RSUs for the period ended September 30, 2023.


	Number of Shares (in 000's)	Weighted Average Grant Date Fair Value
Outstanding at January 1, 2022	459	$	31.08
Granted	802	20.30
Settled	(231)	27.81
Forfeited	(177)	25.53
Outstanding at December 31, 2022	853	$	23.06
Granted	1,312	12.01
Settled	(232)	22.79
Forfeited	(194)	16.84
Nonvested RSUs at September 30, 2023	1,739	$	15.20

Note 8 — Non-Controlling Interests

The following table presents the outstanding membership interests in HoldCo ("LLC Interests") and changes in LLC Interests for the periods presented.


	LLC Interests held			% of Total
$'s in 000's	LLC Owners	PetIQ, Inc.	Total	LLC Owners		PetIQ, Inc.
As of January 1, 2022	272	29,139	29,411	0.9	%	99.1	%
Stock based compensation transactions	—	188	188
Exchange transactions	(20)	20	—
Unit redemption	—	(373)	(373)
As of December 31, 2022	252	28,974	29,226	0.9	%	99.1	%
Stock based compensation transactions	—	197	197
Exchange transactions	(13)	13	—
As of September 30, 2023	239	29,184	29,423	0.8	%	99.2	%

Note that certain figures shown in the table above may not recalculate due to rounding.

For the three and nine months ended September 30, 2023, the Company owned a weighted average of 99.2%, of HoldCo, and for the three and nine months ended September 30, 2022 the Company owned a weighted average of 99.1%, respectively.

Note 9 — Customer Concentration

The Company has significant exposure to customer concentration. During the three and nine months ended September 30, 2023, two customers individually accounted for more than 10% of sales, comprising 36% and 41% of net sales in aggregate, respectively for such periods. During the three and nine months ended September 30, 2022 three customers individually accounted for more than 10% of sales, comprising 44% and 44% of net sales, respectively for such periods.

At September 30, 2023, two Products segment customers individually accounted for more than 10% of outstanding trade receivables, and accounted for 53% of outstanding trade receivables, net. At December 31, 2022, one Products segment customer individually accounted for more than 10% of outstanding trade receivables, and accounted for 46% of outstanding trade receivables, net.

Note 10 — Commitments and Contingencies

Litigation Contingencies

The Company records a liability when a particular contingency is probable and estimable and provides disclosure for contingencies that are at least reasonably possible of resulting in a loss including an estimate which we currently cannot make. The Company has not accrued for any contingency as of September 30, 2023 and December 31, 2022 as the Company does not consider any contingency to be probable or estimable.

During the nine months ended September 30, 2022, the Company recorded $3.5 million of expense associated with a lawsuit brought by a former supplier to the Company relating to the redemption of ownership interest, which is included within selling, general and administrative expenses on the condensed consolidated statements of operations. The matter was settled and paid during 2022.

Commitments

We have commitments for long-term debt that are discussed further in Note - 3, Debt, and leases. In addition, we have purchase obligations for goods and services, capital expenditures, and raw materials entered into in the normal course of business.

Note 11 — Segments

The Company has two operating segments: Products and Services. The Products segment consists of the Company’s manufacturing and distribution business. The Services segment consists of the Company’s veterinary services and related product sales. The segments are based on the discrete financial information reviewed by the Chief Operating Decision Maker (“CODM”) to make resource allocation decisions and to evaluate performance. We measure and evaluate our reportable segments based on their respective Segment Adjusted EBITDA performance. Beginning in the fourth quarter of 2022, we allocate to our segments capital expenditures and certain costs and expenses, such as accounting, legal, human resources, information technology and corporate headquarters expenses, on a pro rata basis based on net sales to better align with the discrete financial information reviewed by our CODM. Such expenses previously were not allocated to segments. The Company has recast prior periods to give effect to this change. This change in presentation had no impact on the Condensed Consolidated Statements of Operations.

Financial information relating to the Company’s operating segments for the three months ended:


$'s in 000's	Products		Services
September 30, 2023
Net sales	$	239,665	$	37,354
Segment Adjusted EBITDA	29,039		2,912
Depreciation expense	1,870		8,981


$'s in 000's	Products		Services
September 30, 2022
Net sales	$	176,217	$	33,508
Segment Adjusted EBITDA	18,282		927
Depreciation expense	1,761		1,815

Financial information relating to the Company’s operating segments for the nine months ended:


$'s in 000's	Products		Services
September 30, 2023
Net sales	$	776,825	$	105,212
Segment Adjusted EBITDA	94,513		5,274
Depreciation expense	5,547		12,989


$'s in 000's	Products		Services
September 30, 2022
Net sales	$	642,981	$	94,453
Segment Adjusted EBITDA	74,095		4,290
Depreciation expense	5,461		5,312

The following table reconciles Segment Adjusted EBITDA to Net income for the periods presented.


	For the three months ended				For the nine months ended
$'s in 000's	September 30, 2023		September 30, 2022		September 30, 2023		September 30, 2022
Segment Adjusted EBITDA:
Products(1)	$	29,039	$	18,282	$	94,513	$	74,095
Services(1)	2,912		927		5,274		4,290
Total	31,951		19,209		99,787		78,385
Adjustments:
Depreciation(2)	(10,851)		(3,576)		(18,536)		(10,773)
Amortization	(4,546)		(4,602)		(15,285)		(13,602)
Interest	(8,581)		(7,276)		(26,137)		(19,696)
Goodwill impairment(3)	—		(47,264)		—		(47,264)
Acquisition costs(4)	122		(1,035)		(713)		(1,191)

Stock based compensation expense	(2,851)		(2,238)		(8,059)		(8,904)
Non same-store adjustment(5)	(2,791)		(2,944)		(7,036)		(13,575)
Integration costs(6)	(484)		(200)		(2,078)		(943)
Restructuring(7)	(1,200)		—		(1,200)		—
Litigation expenses	(30)		—		(30)		(3,802)


Pretax net income (loss)	$	739	$	(49,926)	$	20,713	$	(41,365)
Income tax (expense) benefit	(283)		355		(923)		(368)
Net income (loss)	$	456	$	(49,571)	$	19,790	$	(41,733)

(1) In the fourth quarter of 2022, the Company began allocating corporate expenses to each segment pro rata based on net sales for each segment. The presentation of Products Segment Adjusted EBITDA and Services Segment Adjusted EBITDA for the three and nine months ended September 30, 2022 has been recast for comparability. For the three and nine months ended September 30, 2022, total corporate expenses were $20.7 million, of which $17.4 million was allocated to Products and $3.3 million was allocated to Services, and $60.6 million, of which $52.8 million was allocated to Products and $7.8 million was allocated to Services, respectively.

(2) Depreciation includes $7.3 million of accelerated depreciation recognized during the three and nine months ended September 30, 2023, associated with Services segment optimization.

(3) Non-cash goodwill impairment due to a significant decline in the Company’s market capitalization, driven primarily by rising interest rates and macroeconomic conditions.

(4) Acquisition costs include legal, accounting, banking, consulting, diligence, and other costs related to completed and contemplated acquisitions.

(5) Non same-store adjustment includes revenue and costs, and associated gross profit, related to our Services segment wellness centers and host partners with less than six full quarters of operating results, and also include pre-opening expenses.

(6) Integration costs represent costs related to integrating acquired businesses, including personnel costs such as severance and retention bonuses, consulting costs, contract termination costs and IT conversion costs.

(7) Restructuring consists of variable lease expenses, inventory valuation adjustments and other miscellaneous costs.

Supplemental geographic disclosures are below.


	Three Months Ended September 30, 2023
$'s in 000's	U.S.		Foreign		Total
Product sales	$	237,962	$	1,703	$	239,665
Service revenue	37,354		—		37,354
Total net sales	$	275,316	$	1,703	$	277,019


	Three Months Ended September 30, 2022
$'s in 000's	U.S.		Foreign		Total
Product sales	$	174,517	$	1,700	$	176,217
Service revenue	33,508		—		33,508
Total net sales	$	208,025	$	1,700	$	209,725


	Nine Months Ended September 30, 2023
$'s in 000's	U.S.		Foreign		Total
Product sales	$	772,013	$	4,812	$	776,825
Service revenue	105,212		—		105,212
Total net sales	$	877,225	$	4,812	$	882,037


	Nine Months Ended September 30, 2022
$'s in 000's	U.S.		Foreign		Total
Product sales	$	637,385	$	5,596	$	642,981
Service revenue	94,453		—		94,453
Total net sales	$	731,838	$	5,596	$	737,434

Property, plant, and equipment by geographic location is below.


	September 30, 2023		December 31, 2022
United States	$	58,921	$	69,376
Europe	4,006		4,019
Total	$	62,927	$	73,395

Note 12 — Restructuring

As a result of the optimization, the Company identified 149 underperforming wellness centers for closure. The Company closed 45 wellness centers during the three months ended September 30, 2023, and expects to close the remaining 104 wellness centers in the fourth quarter ending December 31, 2023. The Company ended the third quarter of 2023 with 237 wellness centers and expects to end 2023 with 133 wellness centers. Restructuring and related charges attributable to the optimization were $8.5 million recorded on the condensed consolidated statements of operations for the three and nine months ended September 30, 2023. Total restructuring and related charges are expected to be approximately $14.6 million for the year ending December 31, 2023, including approximately $11.1 million of depreciation and amortization as well as $0.3 million inventory valuation adjustments.

Additionally, not included in restructuring and related costs are approximately $3.0 million of operating lease liabilities on the condensed consolidated balance sheet. Closure of the wellness centers will require the Company to terminate leases

early, which the Company anticipates paying off in the fourth quarter of 2023. In addition to the lease payoff, the Company also expects to pay severance and other termination costs of approximately $3.3 million.

Restructuring charges include accelerated depreciation and amortization, variable lease expenses, and other miscellaneous costs. The remaining costs pertain to variable lease expenses, lease termination costs, severance, and other miscellaneous costs.

Restructuring expenses for the three and nine months ended September 30, 2023 are as follows:


	For the three months ended				For the nine months ended
$'s in 000's	September 30, 2023		September 30, 2022		September 30, 2023		September 30, 2022
Included in Cost of services
Inventory reserve	$	250	$	—	$	250	$	—
Total in Cost of services	250		—		250		—

Included in Restructuring
Accelerated depreciation - property, plant and equipment	$	5,580	$	—	$	5,580	$	—
Accelerated amortization - operating lease right of use assets	1,755		—		1,755		$	—
Other	900		—		900		$	—
Total in Restructuring	8,235		—		8,235		—
Total Restructuring Expenses	$	8,485	$	—	$	8,485	$	—

A roll forward of our liability related to the optimization, which is included in accrued liabilities on our condensed consolidated balance sheets, is as follows (in thousands):


$'s in 000's	Expenses		Cash Payments		Non-Cash Amounts		Liability at September 30, 2023

Accelerated depreciation - property, plant and equipment	$	5,580	$	—	$	(5,580)	$	—
Accelerated amortization - operating lease right of use assets	1,755		—		(1,755)		—
Inventory reserve	250		—		(250)		—

Other	900		—		—		900
Total Restructuring Expenses	$	8,485	$	—	$	(7,585)	$	900

Note 13 — Related Parties

Chris Christensen, the brother of CEO, McCord Christensen, acts as the Company’s agent at Moreton Insurance, which acts as a broker for a number of the Company’s insurance policies. The Company’s premium expense, which is generally paid directly to the relevant insurance company, amounted to $6.6 million and $7.2 million for policies that cover the nine months ended September 30, 2023 and 2022, respectively. Mr. Chris Christensen earns various forms of compensation based on the specifics of each policy.

Katie Turner, the spouse of CEO, McCord Christensen, is the owner of Acadia Investor Relations LLC, (“Acadia”) which acts as the Company’s investor relations consultant. Acadia was paid $0.06 million and $0.2 million for the three and nine months ended September 30, 2023 and 2022, respectively.

Mike Glasman, the brother of CFO, Zvi Glasman, acted as a broker in connection with the Company's entry into a Master Services Agreement with Syndeo, LLC d/b/a Broadvoice ("Broadvoice") in February 2023 for the provision of certain information technology related services. The amount to be paid to Broadvoice over the 39-month agreement is estimated at $0.4 million. $0.01 million was paid to Broadvoice in the three and nine months ended September 30, 2023. Mr. Michael Glasman earns various fees based on the services provided by Broadvoice.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following is a discussion of our results of operations and current financial condition. This should be read in conjunction with the accompanying unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements for the year ended December 31, 2022 and related notes included in the Annual Report on Form 10-K for the year ended December 31 filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2023. This discussion contains forward-looking statements that reflect our plans, estimates, and beliefs and involve numerous risks and uncertainties. Actual results may differ materially from those contained in any forward-looking statements. See “Cautionary Note Regarding Forward-Looking Statements.” Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” refer to PetIQ, Inc. and our consolidated subsidiaries.

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” refer to PetIQ, Inc. and our consolidated subsidiaries.

Business Overview

PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. We engage with customers through more than 60,000 points of distribution across retail and e-commerce channels with our branded and distributed medications as well as health and wellness items, which are further supported by our world-class medications manufacturing facility in Omaha, Nebraska and health and wellness manufacturing facility in Springville, Utah. Our national service platform, operates in over 2,600 retail partner locations in 41 states, providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care that we can give them.

We have two reporting segments: (i) Products; and (ii) Services. The Products segment consists of our manufacturing and distribution business. The Services segments consists of veterinary and wellness services and products provided by the Company directly to consumers.

During the third quarter of 2023, we implemented a Services segment optimization (the "optimization") to improve the functioning of the Services segment and profitability. The optimization included assessing the operational and financial performance of the Company's wellness centers since re-opening after the pandemic as well as the assessment of the veterinary labor market in each geographic market. The Company also evaluated its ability to potentially convert these locations to a more hygiene-focused offering and determined they would be unable to convert these locations in the future based on the aforementioned assessment and the available square footage within the respective wellness centers. As a result of the optimization, the Company identified 149 underperforming wellness centers for closure. The Company closed 45 wellness centers during the three months ended September 30, 2023, and expects to close the remaining 104 wellness centers in the fourth quarter ending December 31, 2023. Restructuring and related charges attributable to the optimization were $8.5 million recorded on the condensed consolidated statements of operations for the three and nine months ended September 30, 2023. Total restructuring and related charges are expected to be approximately $14.6 million for the year ending December 31, 2023, including approximately $11.1 million of depreciation and amortization as well as $0.3 million inventory valuation adjustments. Additionally, not included in restructuring and related costs are approximately $3.0 million of operating lease liabilities on the condensed consolidated balance sheet. Closure of the wellness centers will require the Company to terminate leases early, which the Company anticipates paying off in the fourth quarter of 2023. In addition to the lease payoff, the Company also expects to pay severances and other termination costs of approximately $3.3 million. Restructuring charges include accelerated depreciation and amortization, variable lease expenses, and other miscellaneous costs. The remaining costs pertain to variable lease expenses, lease termination costs, severance, and other miscellaneous costs. For additional information about the restructuring, see "Note 12 - Restructuring" to our condensed consolidated financial statements included herein.

On January 13, 2023, the Company completed the acquisition of all of the membership units of Rocco and Roxie Supply Co, LLC ("R&R"), after which R&R became a wholly owned and consolidated subsidiary of the Company. The acquisition expands the Company's product portfolio to include stain and odor products, jerky treats and behavioral products as well as expands sales channels in e-commerce.

We are the managing member of PetIQ Holdings, LLC (“HoldCo”), a Delaware limited liability company, which is the sole member of PetIQ, LLC (“OpCo”) and, through HoldCo, operates and controls all of the business and affairs of OpCo.

Results of Operations

The following tables set forth our condensed consolidated statements of operations in dollars and as a percentage of net sales for the periods presented:


	For the Three Months Ended				% of Net Sales for the three months ended
$'s in 000's	September 30, 2023		September 30, 2022		September 30, 2023	September 30, 2022
Product sales	$	239,665	$	176,217	86.5%	84.0%
Services revenue	37,354		33,508		13.5%	16.0%
Total net sales	277,019		209,725		100.0%	100.0%
Cost of products sold	174,286		131,414		62.9%	62.7%
Cost of services	30,122		27,541		10.9%	13.1%
Total cost of sales	204,408		158,955		73.8%	75.8%
Gross profit	72,611		50,770		26.2%	24.2%
Selling, general and administrative expenses	55,021		45,984		19.9%	21.9%
Restructuring	8,235		—		3.0%	—%
Goodwill impairment	—		47,264		—%	22.5%
Operating income (loss)	9,355		(42,478)		3.4%	(20.3)%
Interest expense, net	8,581		7,276		3.1%	3.5%

Other expense, net	35		172		—%	0.1%
Total other expense, net	8,616		7,448		3.1%	3.6%
Pretax net income (loss)	739		(49,926)		0.3%	(23.8)%
Income tax (expense) benefit	(283)		355		(0.1)%	0.2%
Net income (loss)	$	456	$	(49,571)	0.2%	(23.6)%


	For the Nine Months Ended				% of Net Sales for the nine months ended
$'s in 000's	September 30, 2023		September 30, 2022		September 30, 2023	September 30, 2022
Product sales	$	776,825	$	642,981	88.1%	87.2%
Services revenue	105,212		94,453		11.9%	12.8%
Total net sales	882,037		737,434		100.0%	100.0%
Cost of products sold	585,616		485,833		66.4%	65.9%
Cost of services	87,671		81,222		9.9%	11.0%
Total cost of sales	673,287		567,055		76.3%	76.9%
Gross profit	208,750		170,379		23.7%	23.1%
Selling, general and administrative expenses	153,507		144,815		17.4%	19.6%
Restructuring	8,235		—		0.9%	—%
Goodwill impairment	—		47,264		—%	6.4%

Operating income (loss)	47,008		(21,700)		5.3%	(2.9)%
Interest expense, net	26,137		19,696		3.0%	2.7%

Other expense (income), net	158		(31)		—%	—%
Total other expense, net	26,295		19,665		3.0%	2.7%
Pretax net income (loss)	20,713		(41,365)		2.3%	(5.6)%
Income tax expense	(923)		(368)		(0.1)%	—%
Net income (loss)	$	19,790	$	(41,733)	2.2%	(5.7)%

Three Months Ended September 30, 2023 Compared With Three Months Ended September 30, 2022

Net sales

Consolidated Net Sales

Consolidated net sales increased $67.3 million or 32.1%, to $277.0 million for the three months ended September 30, 2023, compared to $209.7 million for the three months ended September 30, 2022. Net sales growth of $63.5 million within the Products segment was driven by broad strength across nearly all product categories on strong consumer demand, including distributed flea and tick, prescription medication, and manufacturing categories, as well as sales from the acquisition of R&R, which occurred in January 2023. The Services segment revenues grew by $3.8 million driven by increased dollar per pet served during the third quarter of 2023.

Products Segment

Product sales increased $63.5 million, or 36.0%, to $239.7 million for the three months ended September 30, 2023, compared to $176.2 million for the three months ended September 30, 2022. The increase was driven by broad strength across nearly all categories on strong consumer demand. Additionally, the Company added R&R products related to the acquisition that occurred in January 2023, for which there are no comparable sales in the prior period.

Services Segment

Services revenue increased $3.9 million, or 11.5%, to $37.4 million for the three months ended September 30, 2023, compared to $33.5 million for the three months ended September 30, 2022. Same-store sales increased $5.7 million, or 19.2%, to $35.3 million for the three months ended September 30, 2023, compared to $29.6 million for the three months ended September 30, 2022. The increased service revenue was driven by operational improvements which drove increases in clinic counts, average dollar per clinic, and average dollar per pet served during the third quarter of 2023.

Gross profit

Gross profit increased by $21.9 million, or 43.1%, to $72.6 million for the three months ended September 30, 2023, compared to $50.8 million for the three months ended September 30, 2022. This increase is driven by the Products segment gross profit increasing by $20.6 million due to net sales growth. We also benefited from operating leverage on higher sales and increased manufacturing efficiencies in our plants. Additionally, our Services segment gross profit increased by $1.3 million primarily due to higher sales and operational improvements.

Gross margin increased to 26.2% for the three months ended September 30, 2023, compared to 24.2% for the three months ended September 30, 2022. The increase was primarily due to Products segment gross margin increase of approximately 200 basis points as we benefited from operating leverage on higher sales and increased manufacturing efficiencies in our plants as well as the impact of changes in product mix. We also benefited from operational improvements in the Services segment.

Selling, general and administrative expenses

Consolidated selling, general and administrative expenses (“SG&A”) increased by $9.0 million, or 19.7%, to $55.0 million for the three months ended September 30, 2023, compared to $46.0 million for the three months ended September 30, 2022. As a percentage of net sales, SG&A decreased from 21.9% for the three months ended September 30, 2022 to 19.9% for the three months ended September 30, 2023 on continued leverage of costs and increased business expense efficiencies relative to the growth in sales. The $9.0 million increase was driven by increased corporate compensation expense of $4.0 million, increased marketing costs of $4.9 million to support our branded portfolio, and increased variable R&R expenses of $1.1 million, partially offset by $1.0 million decrease due to Services segment operational improvements.

Products Segment

Products segment SG&A increased $10.0 million or approximately 28.4% to $45.1 million for the three months ended September 30, 2023, compared to $35.1 million for the three months ended September 30, 2022. This increase was primarily due to variable R&R expenses and increased corporate compensation expense. Additionally marketing and advertising increased to support our branded portfolio.

Services Segment

Services segment SG&A decreased $1.0 million, or 8.1%, to $10.0 million for the three months ended September 30, 2023, compared to $10.9 million for the three months ended September 30, 2022. This decrease was driven by operational improvements reducing personnel costs.

Restructuring

During the third quarter of 2023, the Company implemented a Services segment optimization (the "optimization") to improve the functioning of the Services segment and profitability. The optimization included assessing the operational and financial performance of the Company's wellness centers since re-opening after the pandemic as well as the assessment of the veterinary labor market in each geographic market. The Company also evaluated its ability to potentially convert these locations to a more hygiene-focused offering and determined they would be unable to convert these locations in the future based on the aforementioned assessment and the available square footage within the respective wellness centers. As a result of the optimization, the Company identified 149 underperforming wellness centers for closure. The Company closed 45 wellness centers during the three months ended September 30, 2023, and expects to close the remaining 104 wellness centers in the fourth quarter ending December 31, 2023. Restructuring totaled $8.2 million and had no comparable event for the three months ended September 30, 2022.

Goodwill Impairment

During the three months ended September 30, 2022, the Company recorded an impairment charge of $47.3 million related to the write-down of the full goodwill balance of the Services segment, and had no comparable event in the three months ended September 30, 2023.

Interest expense, net

Interest expense, net, increased $1.3 million to $8.6 million for the three months ended September 30, 2023, compared to $7.3 million for the three months ended September 30, 2022. This increase was driven by the higher rates on the Company's variable rate debt due to rising interest rates, partially offset by lower debt balances and interest earned on the Company's cash and cash equivalents.

Provision for income taxes

Our effective tax rate was 38.3% and 0.7% for the three months ended September 30, 2023 and 2022, respectively, with a tax expense of $0.3 million and a tax benefit of $0.4 million, respectively. The tax rate is different than the U.S federal statutory income tax rate of 21% primarily due to the effects of the change in valuation allowance, state taxes, and the foreign rate differential.

Nine Months Ended September 30, 2023 Compared With Nine Months Ended September 30, 2022

Net sales

Consolidated Net Sales

Consolidated net sales increased $144.6 million, or 19.6%, to $882.0 million for the nine months ended September 30, 2023, compared to $737.4 million for the nine months ended September 30, 2022. Net sales growth of $133.8 million within the Products segment was driven by broad strength across nearly all product categories on strong consumer demand, including distributed flea and tick, prescription medication, and manufacturing categories, as well as sales from the acquisition of R&R, which occurred in January 2023. The Services segment revenues grew by $10.7 million driven by increased average dollar per clinic and average dollar per pet served.

Products Segment

Product sales increased $133.8 million, or 20.8%, to $776.8 million for the nine months ended September 30, 2023, compared to $643.0 million for the nine months ended September 30, 2022. This increase was driven by broad strength across nearly all categories, and increased sales of R&R products related to the acquisition that occurred in January 2023, for which there is no comparable sales in the prior period.

Services Segment

Services revenue increased $10.7 million, or 11.4%, to $105.2 million for the nine months ended September 30, 2023, compared to $94.5 million for the nine months ended September 30, 2022. The increased service revenue was driven by operational improvements which drove increases in clinic counts, average dollar per clinic, and average dollar per pet served.

Gross profit

Gross profit increased by $38.4 million, or 22.5%, to $208.8 million for the nine months ended September 30, 2023, compared to $170.4 million for the nine months ended September 30, 2022. This increase is driven by the Products segment gross profit increasing by $34.1 million due to net sales growth, and Services segment gross profit increasing $4.3 million due to operational improvements.

Gross margin increased to 23.7% for the nine months ended September 30, 2023, compared to 23.1% for the nine months ended September 30, 2022. The increase of margin was primarily due to the impact of changes in product mix.

Selling, general and administrative expenses

Consolidated SG&A increased by $8.7 million, or 6.0%, to $153.5 million for the nine months ended September 30, 2023, compared to $144.8 million for the nine months ended September 30, 2022, primarily driven by increases in variable R&R expenses, compensation, amortization expenses related to termination of an in process research and development agreement, and increased marketing spend to support our branded portfolio. Partially offset by decreases in legal expenses and decreased stock compensation expense due to executive departures in the prior year. As a percentage of net sales, SG&A decreased from 19.6% for the nine months ended September 30, 2022 to 17.4% for the nine months ended September 30, 2023, this decrease was driven by operational efficiencies

Products Segment

Products segment SG&A increased $12.0 million or approximately 10.6% to $125.6 million for the nine months ended September 30, 2023, compared to $113.6 million for the nine months ended September 30, 2022. This increase was driven by variable R&R expenses, amortization expenses related to termination of an in process research and development agreement, and increased marketing spend to support our branded portfolio.

Services Segment

Services segment SG&A decreased $3.3 million, or 10.6%, to $27.9 million for the nine months ended September 30, 2023, compared to $31.2 million for the nine months ended September 30, 2022. This decrease was driven by operational improvements and decreased marketing spend.

Restructuring

During the nine months ended September 30, 2023, the Company implemented a Services segment optimization (the "optimization") to improve the functioning of the Services segment and profitability. The optimization included assessing the operational and financial performance of the Company's wellness centers since re-opening after the pandemic as well as the assessment of the veterinary labor market in each geographic market. The Company also evaluated its ability to potentially convert these locations to a more hygiene-focused offering and determined they would be unable to convert these locations in the future based on the aforementioned assessment and the available square footage within the respective wellness centers. As a result of the optimization, the Company identified 149 underperforming wellness centers for closure. The Company closed 45 wellness centers during the nine months ended September 30, 2023, and expects to close the remaining 104 wellness centers in the fourth quarter ending December 31, 2023. Restructuring totaled $8.2 million and had no comparable event for the nine months ended September 30, 2022

Goodwill Impairment

During the nine months ended September 30, 2022, the Company recorded an impairment charge of $47.3 million related to the write-down of the full goodwill balance of the Services segment, and had no comparable event in the nine months ended September 30, 2023.

Interest expense, net

Interest expense, net, increased $6.4 million to $26.1 million for the nine months ended September 30, 2023, compared to $19.7 million for the nine months ended September 30, 2022. This increase was driven by the higher rates on the Company's variable rate debt due to rising interest rates, partially offset by interest earned on the Company's cash and cash equivalents.

Provision for income taxes

Our effective tax rate was 4.5% and (0.9%) for the nine months ended September 30, 2023 and 2022, respectively, with a tax expense of $0.9 million and $0.4 million, respectively. The tax rate is different than the U.S federal statutory income tax rate of 21% primarily due to the effects of a change in valuation allowance, state taxes, and the foreign rate differential.

Consolidated Non-GAAP Financial Measures

EBITDA and Adjusted EBITDA are non-GAAP financial measures. We calculate EBITDA as net income adjusted for income tax expense, depreciation, amortization, goodwill impairment, and interest expense, net. We calculate Adjusted EBITDA as EBITDA adjusted for acquisition costs, stock-based compensation expense, integration and restructuring costs, litigation expenses, and other one-time transactions that management does not believe are representative of our core ongoing business. Adjusted EBITDA is utilized by management in evaluating the Company's performance the effectiveness of our business strategies. The Company presents EBITDA because it is a necessary component for computing Adjusted EBITDA.

We believe that the use of EBITDA and Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends. In addition, you should be aware when evaluating EBITDA and Adjusted EBITDA that in the future we may incur expenses similar to those excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by these or other unusual or non-recurring items. Our computation of EBITDA and Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate EBITDA and Adjusted EBITDA in the same manner.

Beginning in the fourth quarter of 2022, the Company no longer adds back non-same store adjustments in its calculation of

Adjusted EBITDA and has recast prior year periods to reflect this change

Our management does not, and you should not, consider EBITDA or Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of EBITDA and Adjusted EBITDA is that they exclude significant expenses and income that are required by GAAP to be recorded in our financial statements. Some of these limitations are:

•EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;

•EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

•EBITDA does not reflect the interest expenses, or the cash requirements necessary to service interest or principal payments, on our debts;

•Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements;

•Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of our ongoing core operations; and

•Other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

Because of these limitations, EBITDA and Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using EBITDA and Adjusted EBITDA only supplementary. You should review the reconciliations of net income to EBITDA and Adjusted EBITDA below and not rely on any single financial measure to evaluate our business.

The following table reconciles net income to EBITDA and Adjusted EBITDA for the periods presented.


	For the Three Months Ended				For the Nine Months Ended
$'s in 000's	September 30, 2023		September 30, 2022		September 30, 2023		September 30, 2022
Net income (loss)	$	456	$	(49,571)	$	19,790	$	(41,733)
Plus:
Tax expense (benefit)	283		(355)		923		368
Depreciation(1)	10,851		3,576		18,536		10,773
Amortization	4,546		4,602		15,285		13,602
Goodwill impairment(2)	—		47,264		—		47,264
Interest expense, net	8,581		7,276		26,137		19,696
EBITDA	$	24,717	$	12,792	$	80,671	$	49,970
Acquisition costs(3)	—		1,035		713		1,191

Stock based compensation expense	2,851		2,238		8,059		8,904

Integration costs(4)	484		200		2,078		943
Restructuring(5)	1,200		—		1,200		—
Litigation expenses	30		—		30		3,802
Adjusted EBITDA	$	29,282	$	16,265	$	92,751	$	64,810

(1) Depreciation includes $7.3 million of accelerated depreciation recognized during the three and nine months ended September 30, 2023, associated with Services segment optimization.

(2) Non-cash goodwill impairment due to a significant decline in the Company’s market capitalization, driven primarily by rising interest rates and macroeconomic conditions.

(3) Acquisition costs include legal, accounting, banking, consulting, diligence, and other costs related to completed and contemplated acquisitions.

(4) Integration costs represent costs related to integrating acquired businesses, including personnel costs such as severance and retention bonuses, consulting costs, contract termination costs and IT conversion costs.

(5) Restructuring consists of variable lease expenses, inventory valuation adjustments and other miscellaneous costs.

Financial Condition, Liquidity, and Capital Resources

Historically, our primary sources of liquidity have been cash flows from operations, borrowings, and equity financing. As of September 30, 2023 and December 31, 2022, our cash and cash equivalents were $124.6 million and $101.3 million, respectively. As of September 30, 2023, we had an unused revolving credit facility with availability of $125.0 million, $293.3 million outstanding under our term loan, $143.8 million of outstanding convertible notes, and $16.6 million in other debt. Our debt agreements bear interest at rates between 4.0% and 9.84%. See “Note 3 – Debt” to our condensed consolidated financial statements included herein for a description of each of our debt arrangements.

Our primary cash needs are for working capital. Our maintenance capital expenditures have typically been less than 1.0% of net sales, but we may make additional capital expenditures as necessary to support our growth. Our primary working capital requirements are to fund inventory and accounts receivable to support our sales. Fluctuations in working capital are primarily driven by the timing of new product launches and seasonal retailer demand. As of September 30, 2023 and December 31, 2022, we had working capital (current assets less current liabilities) of $246.0 million and $220.6 million, respectively. The Company has not historically made significant non-contractual debt pay downs, but may choose to do so in the future as part of its capital allocation strategy.

We believe that our operating cash flow, cash on hand, and debt proceeds from our borrowings under our debt facilities will be adequate to meet our operating, investing, and financing needs for at least the next 12 months. We believe we will

meet our longer-term expected future cash requirements primarily from a combination of cash flow from operating activities, borrowings under our debt facilities and available cash and cash equivalents. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, equity financings, or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms or at all. As in the past, we will continue to explore opportunities to optimize our capital structure.

Cash Flows

Cash provided by (used in) Operating Activities

Net cash provided by operating activities was $64.7 million for the nine months ended September 30, 2023, compared to $0.9 million used in operating activities for the nine months ended September 30, 2022. The change in operating cash flows primarily reflects higher profitability and increased cash provided from working capital of $42.3 million. Working capital changes are driven primarily by growth in accounts receivable, which is related to higher sales, and cash provided by decreases in inventory as a result of increased consumption in the current year. In the prior year period inventory growth required significant cash outlays due to the unusually low inventory at the beginning of 2022. Wages payable and interest payable also accounted for large changes to working capital.

Cash used in Investing Activities

Net cash used in investing activities was $33.8 million for the nine months ended September 30, 2023, compared to $9.8 million for the nine months ended September 30, 2022. The increase in net cash used in investing activities was primarily the result of $27.6 million of the cash utilized in the acquisition of R&R partially offset by lower purchases of fixed assets.

Cash used in Financing Activities

Net cash used in financing activities was $7.8 million for the nine months ended September 30, 2023, compared to $11.4 million for the nine months ended September 30, 2022. The change in cash used in financing activities is primarily driven by stock repurchase made in the prior year period with no comparable events in the current period.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

We are exposed to certain market risks arising from transactions in the normal course of our business. Such risk is principally associated with interest rates. We currently do not enter into derivatives or other financial instruments for trading or speculative purposes.

Interest Rate Risk

We are exposed to changes in interest rates because the indebtedness incurred under our ABL and our Term Loan B are variable rate debt. Interest rate changes generally do not affect the recorded value of our credit agreements but do affect the amount of our interest payments and, therefore, our future earnings and cash flows. As of September 30, 2023, we had variable rate debt of approximately $304.3 million, primarily under our Revolver and Term Loan. An increase of 1% would have increased our interest expense for the three months ended September 30, 2023 by approximately $0.8 million.

Inflation

Inflation is a factor in our business and we continue to seek ways to mitigate its effect. Inflation has affected our performance in terms of higher costs for employee compensation and benefits, products that we distribute, and components of products we manufacture. We believe the effects of inflation, if any, on our historical results of operations and financial condition have not been material as we have been able to effectively implement price adjustments to pass-through the additional costs. However, in the future, we may not be able to increase prices to our customers sufficiently to offset these increased costs.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that as of such date, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended September 30, 2023, certain processes and controls were modified in connection with the migration of our Springville, Utah facility to our consolidated enterprise resource planning system. We do not believe that such modifications materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

There was no other change in our internal control over financial reporting that occurred during our fiscal quarter ended September 30, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

We are from time to time subject to and/or are presently involved in, litigation and other proceedings. We believe that there are no pending lawsuits or claims that, individually or in the aggregate, may have a material adverse effect on our business, financial condition or results of operations.

The Company records a liability when a particular contingency is both probable and estimable. If the probable loss cannot be reasonably estimated, no accrual is recorded, but the loss contingency and the reasons to the effect that it cannot be reasonably estimated are disclosed. If a loss is reasonably possible, the Company will provide disclosure to that effect. The Company expenses legal costs as incurred within selling, general and administrative expenses on the condensed consolidated statements of operations. For information on legal proceedings, please refer to "Note 10 — Commitments and Contingencies" in the Notes to the Condensed Consolidated Financial Statements included in Part I Item 1 of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors.

Factors that could cause our actual results to differ materially from those in this report are any of the risks disclosed in our Annual Report on Form 10-K, which was filed with the SEC on February 28, 2023, as supplemented by the risk factor set forth below. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

We may not fully realize the anticipated benefits of our Services segment restructuring efforts.

During the third quarter of 2023, we implemented a Services segment optimization (the "optimization") to improve the functioning of the Services segment and profitability. The optimization included assessing the operational and financial performance of the Company's wellness centers since re-opening after the pandemic as well as the assessment of the veterinary labor market in each geographic market. The Company also evaluated its ability to potentially convert these locations to a more hygiene-focused offering and determined they would be unable to convert these locations in the future based on the aforementioned assessment and the available square footage within the respective wellness centers. As a result of the optimization, the Company identified 149 underperforming wellness centers for closure. The Company closed 45 wellness centers during the three months ended September 30, 2023, and expects to close the remaining 104 wellness centers in the fourth quarter ending December 31, 2023. Restructuring and related charges attributable to the optimization were $8.5 million recorded on the condensed consolidated statements of operations for the three and nine months ended September 30, 2023. Total restructuring and related charges are expected to be approximately $14.6 million for the year ending December 31, 2023, including approximately $11.1 million of depreciation and amortization as well as $0.3 million inventory valuation adjustments. Our ability to improve profitability and achieve the anticipated cost savings from the optimization, as well as our ability to reinvest those cost savings into other areas of our business, is subject to many estimates and assumptions, some of which are beyond our control. If our estimates and assumptions are incorrect or if other unforeseen events occur, we may not achieve the benefits of the optimization and our business and results of operations could be adversely affected.

Item 2. Unregistered Sales of Equity Securities and Results of Operations

On September 6, 2022, the Company's Board of Directors authorized a stock repurchase program for up to $30 million of the Company’s outstanding shares of Class A common stock. Repurchases of Class A common stock may be made at management’s discretion from time to time in one or more transactions on the open market or in privately negotiated purchase and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations promulgated under Securities Exchange Act. The Company did not purchase any shares during the quarter ended September 30, 2023. As of September 30, 2023, $26.1 million in aggregate dollar value of shares remained available for purchase under the stock repurchase program.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Trading Plans

During the three months ended September 30, 2023, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as such term is defined in Item 408(a) of Regulation S-K.

Costs Associated with Exit or Disposal Activities

During the third quarter of 2023, the Company implemented a Services segment optimization (the "optimization") to improve the functioning of the Services segment and profitability. The optimization included assessing the operational and financial performance of the Company's wellness centers since re-opening after the pandemic as well as the assessment of the veterinary labor market in each geographic market. The Company also evaluated its ability to potentially convert these locations to a more hygiene-focused offering and determined they would be unable to convert these locations in the future based on the aforementioned assessment and the available square footage within the respective wellness centers. As a result of the optimization, the Company identified 149 underperforming wellness centers for closure. On November 2, 2023, the Company announced efforts to close 104 wellness centers in the fourth quarter ending December 31, 2023 and also announced that it permanently closed 45 wellness centers that were temporarily closed due to veterinary labor shortages during the three months ended September 30, 2023. Restructuring and related charges attributable to the optimization were $8.5 million recorded on the condensed consolidated statements of operations for the three and nine months ended September 30, 2023. Total restructuring and related charges are expected to be approximately $14.6 million for the year

ending December 31, 2023, including approximately $11.1 million of depreciation and amortization as well as $0.3 million inventory valuation adjustments.

Item 6. Exhibits.


31.1*			Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*			Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**			Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**			Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*			Inline XBRL Instance Document
101.SCH*			Inline XBRL Taxonomy Extension Schema Document
101.CAL*			Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*			Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*			Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF*			Inline XBRL Taxonomy Extension Definition Linkbase Document.
104*			Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)

* Filed herewith

** Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			PETIQ, INC.

November 7, 2023			/s/ Zvi Glasman
			Zvi Glasman
			Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer)

Document

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, McCord Christensen, certify that:

1.I have reviewed this quarterly report on Form 10-Q of PetIQ, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: November 7, 2023
			/s/ McCord Christensen
			McCord Christensen Chief Executive Officer

Document

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Zvi Glasman, certify that:

1.I have reviewed this quarterly report on Form 10-Q of PetIQ, Inc.;

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: November 7, 2023
			/s/ Zvi Glasman
			Zvi Glasman Chief Financial Officer

Document

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of PetIQ, Inc. (the “Company”) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, McCord Christensen, Chief Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


			/s/ McCord Christensen

			McCord Christensen Chief Executive Officer

Date: November 7, 2023

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of PetIQ, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

Document

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of PetIQ, Inc. (the “Company”) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Zvi Glasman, Chief Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


			/s/ Zvi Glasman

			Zvi Glasman Chief Financial Officer
Date: November 7, 2023